139 citations,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
70 citations,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
96 citations,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
72 citations,
July 2014 in “American journal of clinical dermatology” Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.
110 citations,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.
49 citations,
November 2013 in “JAMA dermatology” Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
391 citations,
January 2010 in “Journal of The American Academy of Dermatology” Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.
295 citations,
January 2006 in “Journal of the American Academy of Dermatology” Alopecia areata, a common autoimmune hair loss condition, often runs in families.